In_IN Vitro_NP and_CC In_IN Vivo_NP Synergy_NP of_IN Fosmidomycin_NP ,_, a_DT Novel_NP Antimalarial_JJ Drug_NN ,_, with_IN Clindamycin_NP Fosmidomycin_NP acts_VBZ through_IN inhibition_NN of_IN 1-deoxy-d-xylulose_JJ 5-phosphate_NN (_( DOXP_NP )_) reductoisomerase_NN ,_, a_DT key_JJ enzyme_NN of_IN the_DT nonmevalonate_JJ pathway_NN of_IN isoprenoid_JJ biosynthesis_NN ._SENT It_PP possesses_VBZ potent_JJ antimalarial_JJ activity_NN in_IN vitro_NN and_CC in_IN murine_JJ malaria_NN ._SENT In_IN a_DT recent_JJ clinical_JJ study_NN ,_, fosmidomycin_NN was_VBD effective_JJ and_CC well_RB tolerated_VBN in_IN the_DT treatment_NN of_IN patients_NNS with_IN acute_JJ uncomplicated_JJ Plasmodium_NN falciparum_NN malaria_NN but_CC resulted_VBD in_IN an_DT unacceptably_RB high_JJ rate_NN of_IN recrudescence_NN ._SENT In_IN order_NN to_TO identify_VB a_DT potential_JJ combination_NN partner_NN ,_, the_DT interaction_NN of_IN fosmidomycin_NN with_IN a_DT number_NN of_IN antimalarial_JJ drugs_NNS in_IN current_JJ use_NN was_VBD investigated_VBN in_IN a_DT series_NN of_IN in_IN vitro_NN experiments_NNS ._SENT Synergy_NN was_VBD observed_VBN between_IN fosmidomycin_NN and_CC the_DT lincosamides_NNS ,_, lincomycin_NN and_CC clindamycin_NN ._SENT The_DT efficacy_NN of_IN a_DT combination_NN of_IN fosmidomycin_NN and_CC clindamycin_NN was_VBD subsequently_RB demonstrated_VBN in_IN the_DT Plasmodium_NP vinckei_NP mouse_NN model_NN ._SENT In_IN humans_NNS ,_, isoprenoids_NNS are_VBP synthesized_VBN via_IN the_DT mevalonate_JJ pathway_NN ._SENT In_IN contrast_NN ,_, they_PP are_VBP synthesized_VBN by_IN the_DT nonmevalonate_JJ pathway_NN (_( the_DT 1-deoxy-d-xylulose_JJ 5-phosphate_NN [_SYM DOXP_NP ]_SYM pathway_NN ,_, also_RB called_VBD the_DT MEP_JJ pathway_NN )_) in_IN a_DT number_NN of_IN bacterial_JJ species_NNS and_CC inside_IN the_DT plastides_NNS of_IN algae_NN and_CC higher_JJR plants_NNS ._SENT Similarly_RB ,_, the_DT enzymes_NNS of_IN the_DT nonmevalonate_JJ pathway_NN are_VBP located_VBN inside_IN the_DT plastide-like_JJ organelle_NN (_( apicoplast_NN )_) of_IN malaria_NN parasites_NNS ._SENT The_DT antibiotic_JJ fosmidomycin_NN ,_, originally_RB isolated_VBN from_IN Streptomyces_NP lavendulae_NNS ,_, represents_VBZ a_DT potent_JJ inhibitor_NN of_IN DOXP_NP reductoisomerase_NN ,_, a_DT key_JJ enzyme_NN of_IN the_DT nonmevalonate_JJ pathway_NN ._SENT Recently_RB ,_, it_PP was_VBD demonstrated_VBN that_IN fosmidomycin_NN possesses_VBZ potent_JJ antimalarial_JJ activity_NN in_IN vitro_NN and_CC in_IN murine_JJ malaria_NN ._SENT FR900098_NP ,_, a_DT fosmidomycin_NN derivative_JJ ,_, was_VBD found_VBN to_TO be_VB twice_RB as_RB effective_JJ ,_, while_IN the_DT prodrug_NN derivatives_NNS had_VBD increased_VBN oral_JJ bioavailability_NN in_IN the_DT mouse_NN model_NN ._SENT In_IN a_DT recent_JJ clinical_JJ study_NN conducted_VBN in_IN Gabon_NP and_CC Thailand_NP ,_, 20_CD patients_NNS with_IN acute_JJ uncomplicated_JJ Plasmodium_NN falciparum_NN malaria_NN were_VBD treated_VBN with_IN fosmidomycin_NN administered_VBN orally_RB (_( B._NP Lell_NP ,_, R._NP Ruangweerayut_NP ,_, J._NP Wiesner_NP ,_, M._NP Missinou_NP ,_, A._NP Schindler_NP ,_, T._NP Baranek_NP ,_, M._NP Hintz_NP ,_, D._NP Hutchinson_NP ,_, H._NP Jomaa_NP ,_, and_CC P._NP Kremsner_NP ,_, unpublished_JJ data_NNS )_) ._SENT The_DT treatment_NN was_VBD well_RB tolerated_VBN and_CC resulted_VBN in_IN rapid_JJ parasite_NN and_CC fever_NN clearance_NN times_NNS ,_, comparable_JJ to_TO those_DT obtained_VBN with_IN conventional_JJ quinoline_NN antimalarial_JJ agents_NNS ._SENT All_DT patients_NNS were_VBD clinically_RB and_CC parasitologically_RB cured_VBN by_IN day_NN 7_CD ._SENT By_IN day_NN 28_CD ,_, however_RB ,_, 9_CD out_IN of_IN 18_CD evaluable_JJ patients_NNS experienced_JJ recrudescence_NN ._SENT A_DT similarly_RB high_JJ rate_NN of_IN recrudescence_NN had_VBD been_VBN observed_VBN previously_RB when_WRB the_DT hydroxynaphthoquinone_JJ antimalarial_JJ agent_NN atovaquone_NN was_VBD evaluated_VBN as_IN a_DT single_JJ entity_NN ._SENT Subsequently_RB ,_, proguanil_NP was_VBD identified_VBN as_IN a_DT partner_NN for_IN atovaquone_NN on_IN the_DT basis_NN of_IN in_IN vitro_NN synergistic_JJ activity_NN ,_, resulting_VBG in_IN a_DT highly_RB effective_JJ and_CC well-tolerated_JJ fixed_VBN drug_NN combination_NN ,_, approved_VBN and_CC marketed_VBN as_IN Malarone_NP ._SENT Using_VBG a_DT similar_JJ approach_NN ,_, we_PP have_VBP investigated_VBN the_DT interaction_NN of_IN fosmidomycin_NN with_IN most_JJS antimalarial_JJ agents_NNS in_IN clinical_JJ use_NN ._SENT Materials_NNS ._SENT |_SYM Blood_NP components_NNS were_VBD provided_VBN by_IN the_DT local_JJ Institute_NP of_IN Clinical_NP Immunology_NP and_CC Transfusion_NP Medicine_NP ._SENT Chloroquine_NN ,_, quinine_NN ,_, artemisinin_NP ,_, doxycycline_NN ,_, ciprofloxacin_NP ,_, rifampin_NN ,_, and_CC lincomycin_NN were_VBD purchased_VBN from_IN Sigma_NP ._SENT Mefloquine_NP and_CC halofantrine_NP were_VBD gifts_NNS from_IN Reto_NP Brun_NP (_( Basel_NP ,_, Switzerland_NP )_) ._SENT Atovaquone_NP was_VBD a_DT gift_NN from_IN Peter_NP Kremsner_NP (_( Tubingen_NP ,_, Germany_NP )_) ._SENT Proguanil_NP was_VBD a_DT gift_NN from_IN Wallace_NP Peters_NP and_CC Brian_NP Robinson_NP (_( Harrow_NP ,_, Middlesex_NP ,_, United_NP Kingdom_NP )_) ._SENT Lumefantrine_NP was_VBD provided_VBN by_IN Welding_NP GmbH_NP &_CC Co._NP (_( Hamburg_NP ,_, Germany_NP )_) ._SENT Azithromycin_NP was_VBD extracted_VBN from_IN Zithromax_NP tablets_NNS (_( Pfizer_NP )_) ._SENT Clindamycin_NN was_VBD purchased_VBN from_IN Sigma_NP ,_, ICN_NP ,_, and_CC Welding_NP GmbH_NP &_CC Co._NP The_DT P._NP falciparum_NN laboratory_NN strains_NNS used_VBN were_VBD 3D7_JJ (_( The_DT Netherlands_NPS )_) ,_, HB3_NP (_( Honduras_NP )_) ,_, Dd2_NP (_( Indochina_NP )_) ,_, and_CC A2_NP (_( Gambia_NP )_) ._SENT The_DT Plasmodium_NP vinckei_NN strain_NN was_VBD provided_VBN by_IN Henri_NP Vial_NP (_( Montpellier_NP ,_, France_NP )_) ._SENT In_IN vitro_NN antimalarial_JJ activity_NN ._SENT |_SYM P._NP falciparum_NN was_VBD cultivated_VBN in_IN RPMI_NP 1640_CD medium_NN (_( Life_NP Technologies_NP )_) supplemented_VBD with_IN 10_CD %_NN human_JJ type_NN O+_NP serum_NN and_CC 25_CD mM_NP HEPES_NP ._SENT Human_JJ type_NN O+_NN erythrocytes_NNS served_VBN as_IN host_NN cells_NNS ._SENT Cultures_NNS were_VBD kept_VBN at_IN 37C_JJ under_IN an_DT atmosphere_NN of_IN 5_CD %_NN O2_NP ,_, 3_CD %_NN CO2_NN ,_, and_CC 92_CD %_NN N2_NN ._SENT In_IN vitro_NN drug_NN sensitivity_NN assays_NNS were_VBD carried_VBN out_RP on_IN 96-well_NN microtitration_NN plates_NNS ._SENT Fosmidomycin_NP was_VBD dissolved_VBN in_IN complete_JJ culture_NN medium_NN and_CC sterilized_VBN by_IN filtration_NN ._SENT The_DT other_JJ drugs_NNS were_VBD dissolved_VBN in_IN dimethyl_NN sulfoxide_NN and_CC prediluted_JJ with_IN complete_JJ culture_NN medium_NN ._SENT Infected_JJ erythrocytes_NNS (_( 0.15_CD ml_NN per_IN well_RB with_IN 2_CD %_NN hematocrit_NN and_CC 0.4_CD %_NN parasitemia_NN )_) were_VBD incubated_VBN in_IN duplicate_NN with_IN a_DT twofold_JJ serial_JJ dilution_NN of_IN each_DT drug_NN for_IN 48_CD h._NN After_IN addition_NN of_IN 0.8_CD muCi_NNS of_IN [_SYM 3H]hypoxanthine_JJ (_( Amersham_NP Pharmacia_NP )_) in_IN 50_CD mul_NN of_IN medium_NN per_IN well_RB ,_, the_DT plates_NNS were_VBD incubated_VBN for_IN another_DT 24_CD h._JJ Parasites_NNS were_VBD collected_VBN on_IN glass_NN fiber_NN filters_NNS with_IN a_DT cell_NN harvester_NN (_( Micromate_NP 196_CD ;_: Packard_NP )_) ,_, and_CC incorporated_JJ radioactivity_NN was_VBD measured_VBN using_VBG a_DT beta-counter_NN (_( Matrix_NP 9600_CD ;_: Packard_NP )_) ._SENT Growth_NN inhibition_NN was_VBD expressed_VBN as_IN percent_NN 3H_JJ incorporation_NN compared_VBN with_IN untreated_JJ controls_NNS ._SENT Values_NNS were_VBD plotted_VBN on_IN semilogarithmic_JJ paper_NN for_IN extrapolation_NN of_IN 50_CD %_NN inhibitory_JJ concentrations_NNS (_( IC50s_NP )_) ._SENT In_IN vitro_NN drug_NN interaction_NN ._SENT |_SYM Drug_NP interaction_NN studies_NNS were_VBD performed_VBN as_IN previously_RB described_VBN ._SENT Initially_RB ,_, the_DT IC50s_NP of_IN the_DT test_NN drugs_NNS alone_RB were_VBD determined_VBN ._SENT Subsequently_RB ,_, drug_NN solutions_NNS were_VBD diluted_VBN with_IN culture_NN medium_NN to_TO initial_JJ concentrations_NNS of_IN 80_CD times_NNS the_DT predetermined_VBN IC50s_NP ._SENT These_DT solutions_NNS were_VBD combined_VBN in_IN ratios_NNS of_IN 1:5_CD ,_, 1:2_CD ,_, 2:1_CD ,_, and_CC 5:1_CD ._SENT Single_JJ and_CC combination_NN drug_NN solutions_NNS were_VBD then_RB introduced_VBN into_IN 96-well_NN plates_NNS to_TO give_VB duplicate_JJ rows_NNS of_IN fosmidomycin_NN alone_RB ,_, the_DT test_NN drug_NN ,_, and_CC the_DT four_CD combinations_NNS ._SENT Finally_RB ,_, the_DT IC50s_NP of_IN the_DT two_CD test_NN drugs_NNS alone_RB and_CC in_IN combination_NN were_VBD determined_VBN ._SENT For_IN data_NN interpretation_NN ,_, the_DT IC50s_NP of_IN the_DT drugs_NNS in_IN combination_NN were_VBD expressed_VBN as_IN fractions_NNS of_IN the_DT IC50s_NP of_IN the_DT drugs_NNS alone_RB normalized_VBD to_TO 1_CD ._SENT Isobolograms_NNS were_VBD constructed_VBN by_IN plotting_VBG the_DT IC50_NN of_IN one_CD drug_NN against_IN the_DT IC50_NN of_IN the_DT other_JJ for_IN each_DT of_IN the_DT four_CD drug_NN ratios_NNS ,_, with_IN a_DT concave_JJ curve_NN indicating_VBG synergy_NN ,_, a_DT straight_JJ line_NN indicating_VBG addition_NN ,_, and_CC a_DT convex_JJ curve_NN indicating_VBG antagonism_NN ._SENT To_TO obtain_VB numeric_JJ values_NNS for_IN the_DT kind_NN of_IN interaction_NN ,_, results_NNS were_VBD expressed_VBN as_IN the_DT sum_NN of_IN the_DT fractional_JJ inhibitory_JJ concentrations_NNS (_( sum_NN FIC_NP )_) ,_, calculated_VBN as_IN (_( IC50_NP of_IN drug_NN A_DT in_IN mixture/IC50_NN of_IN drug_NN A_DT alone_RB )_) +_SYM (_( IC50_NP of_IN drug_NN B_NN in_IN mixture/IC50_NN of_IN drug_NN B_NN alone_JJ )_) ._SENT Sum_NP FIC_NP values_NNS indicate_VBP the_DT kinds_NNS of_IN interactions_NNS as_RB follows_VBZ :_: <0.5,_synergy; 2_LS ,_, antagonism_NN ._SENT Sum_NP FIC_NP values_NNS were_VBD calculated_VBN for_IN the_DT drug_NN ratio_NN resulting_VBG in_IN the_DT point_NN closest_JJS to_TO the_DT middle_NN of_IN the_DT isobologram_NN ._SENT For_IN determination_NN of_IN growth_NN inhibition_NN by_IN fosmidomycin_NN in_IN the_DT presence_NN of_IN constant_JJ clindamycin_NN concentrations_NNS ,_, 20-ml_JJ aliquots_NNS of_IN the_DT suspension_NN of_IN infected_JJ erythrocytes_NNS in_IN culture_NN medium_NN were_VBD adjusted_VBN to_TO the_DT desired_VBN clindamycin_NN concentration_NN from_IN a_DT 2_CD mM_NP stock_NN solution_NN in_IN dimethyl_NN sulfoxide_NN before_IN being_VBG loaded_VBN in_IN triplicated_VBN rows_NNS onto_IN the_DT 96-well_NN plate_NN ._SENT Then_RB a_DT dilution_NN series_NN of_IN fosmidomycin_NN was_VBD prepared_VBN on_IN the_DT plate_NN ._SENT In_IN vivo_JJ drug_NN interaction_NN ._SENT |_SYM For_IN in_IN vivo_JJ drug_NN testing_NN ,_, mice_NNS were_VBD inoculated_VBN by_IN intraperitoneal_JJ injection_NN with_IN approximately_RB 5_CD x_SYM 107_CD infected_JJ erythrocytes_NNS from_IN a_DT donor_NN mouse_NN ._SENT Fosmidomycin_NP was_VBD dissolved_VBN in_IN phosphate-buffered_JJ saline_NN and_CC administered_VBN orally_RB (_( 75_CD mg/kg_NN of_IN body_NN weight_NN )_) ._SENT Clindamycin_NN hydrochloride_NN was_VBD dissolved_VBN in_IN distilled_JJ water_NN and_CC administered_VBN by_IN intraperitoneal_JJ injection_NN (_( 5_CD mg/kg_NN )_) ._SENT Four_CD mice_NNS were_VBD used_VBN for_IN each_DT treatment_NN group_NN ,_, and_CC three_CD mice_NNS were_VBD used_VBN for_IN the_DT control_NN group_NN ._SENT Parasitemia_NP was_VBD monitored_VBN by_IN Giemsa_NP staining_VBG of_IN blood_NN smears_NNS ._SENT Mice_NNS were_VBD sacrificed_VBN when_WRB parasitemia_NNS exceeded_VBD 40_CD %_NN ._SENT The_DT animal_JJ experiments_NNS complied_VBN with_IN all_DT relevant_JJ federal_JJ guidelines_NNS and_CC institutional_JJ policies_NNS ._SENT In_IN vitro_NN drug_NN interaction_NN ._SENT |_SYM Before_IN we_PP embarked_VBD on_IN the_DT identification_NN of_IN a_DT therapeutic_JJ partner_NN for_IN fosmidomycin_NN ,_, a_DT control_NN experiment_NN was_VBD performed_VBN to_TO validate_VB the_DT methodology_NN through_IN assessment_NN of_IN the_DT interaction_NN between_IN atovaquone_NP and_CC proguanil_NP ,_, a_DT proven_JJ synergistic_JJ drug_NN combination_NN ._SENT As_IN expected_VBN ,_, the_DT IC50s_NP of_IN the_DT individual_JJ drugs_NNS in_IN the_DT four_CD different_JJ mixtures_NNS were_VBD significantly_RB lower_JJR than_IN the_DT IC50s_NP of_IN the_DT drugs_NNS alone_RB ,_, resulting_VBG in_IN a_DT concave_JJ curve_NN in_IN the_DT isobologram_NN ._SENT Subsequently_RB ,_, fosmidomycin_NN was_VBD tested_VBN in_IN combination_NN with_IN most_JJS of_IN the_DT currently_RB used_VBN antimalarial_JJ drugs_NNS ._SENT The_DT antifolate_JJ drugs_NNS ,_, pyrimethamine_NN and_CC cycloguanil_NN ,_, were_VBD excluded_VBN from_IN the_DT study_NN because_IN of_IN the_DT existence_NN of_IN highly_RB resistant_JJ P._NP falciparum_NN strains_NNS in_IN the_DT field_NN ._SENT The_DT study_NN was_VBD performed_VBN with_IN four_CD different_JJ strains_NNS of_IN P._NP falciparum_NN including_VBG the_DT multidrug-resistant_JJ strain_NN Dd2_NP (_( resistant_JJ to_TO chloroquine_NN ,_, pyrimethamine_NN ,_, and_CC cycloguanil_NNS )_) ._SENT The_DT absolute_JJ IC50s_NN of_IN the_DT drugs_NNS used_VBN in_IN the_DT study_NN for_IN the_DT different_JJ strains_NNS are_VBP listed_VBN in_IN Table_NP ._SENT In_IN the_DT interaction_NN experiments_NNS ,_, there_EX was_VBD no_DT apparent_JJ specific_JJ tendency_NN for_IN any_DT strain_NN ._SENT Typical_JJ isobolograms_NNS are_VBP shown_VBN in_IN Fig._NN ,_, and_CC the_DT sum_NN FIC_JJ values_NNS for_IN all_DT drug_NN combinations_NNS tested_VBN are_VBP summarized_VBN in_IN Table_NP ._SENT The_DT interaction_NN of_IN fosmidomycin_NN with_IN all_DT quinoline_NN and_CC aryl-amino-alcohol_NN antimalarial_JJ drugss_NP was_VBD indifferent_JJ ,_, with_IN the_DT exception_NN of_IN quinine_NN ,_, for_IN which_WDT the_DT interaction_NN was_VBD additive_JJ ._SENT Also_RB ,_, artemisinin_NP ,_, atovaquone_NN ,_, and_CC proguanil_NP had_VBD indifferent_JJ effects_NNS ._SENT In_IN addition_NN ,_, a_DT triple_JJ combination_NN of_IN fosmidomycin_NN ,_, proguanil_NP ,_, and_CC atovaquone_NN was_VBD tested_VBN but_CC also_RB resulted_VBN in_IN an_DT indifferent_JJ effect_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Among_IN the_DT antibiotics_NNS with_IN known_VBN antimalarial_JJ activity_NN ,_, doxycycline_NN and_CC azithromycin_NN were_VBD additive_JJ ,_, and_CC ciprofloxacin_NN and_CC rifampin_NN were_VBD indifferent_JJ ._SENT Synergy_NN was_VBD observed_VBN only_RB with_IN clindamycin_NN and_CC its_PP$ natural_JJ precursor_NN ,_, lincomycin_NN ._SENT Remarkably_RB ,_, the_DT shapes_NNS of_IN the_DT corresponding_JJ isobolograms_NNS were_VBD asymmetric_JJ ,_, in_IN contrast_NN to_TO the_DT curve_NN obtained_VBN in_IN the_DT control_NN experiment_NN with_IN atovaquone_NP and_CC proguanil_NP ._SENT To_TO assess_VB whether_IN the_DT synergy_NN of_IN fosmidomycin_NN and_CC clindamycin_NN is_VBZ of_IN clinical_JJ relevance_NN ,_, it_PP should_MD be_VB noted_VBN that_IN clindamycin_NN is_VBZ an_DT effective_JJ but_CC very_RB slow_VB acting_VBG antimalarial_JJ drug_NN ._SENT Therefore_RB ,_, the_DT absolute_JJ IC50s_NN of_IN clindamycin_NN obtained_VBN under_IN our_PP$ assay_NN conditions_NNS were_VBD comparatively_RB high_JJ ._SENT At_IN lower_JJR concentrations_NNS of_IN clindamycin_NN ,_, the_DT parasites_NNS develop_VBP normally_RB in_IN the_DT first_JJ cycle_NN after_IN exposure_NN ,_, and_CC reinvasion_NN of_IN new_JJ host_NN erythrocytes_NNS takes_VBZ place_NN ._SENT Growth_NN inhibition_NN finally_RB occurs_VBZ at_IN the_DT end_NN of_IN the_DT second_JJ cycle_NN (_( the_DT so-called_JJ "_`` delayed_JJ kill_NN effect_NN "_'' )_) ._SENT Consistently_RB ,_, for_IN patients_NNS treated_VBN with_IN clindamycin_NN ,_, amelioration_NN of_IN symptoms_NNS is_VBZ observed_VBN as_IN late_JJ as_IN the_DT fourth_JJ day_NN of_IN treatment_NN ._SENT Fosmidomycin_NP ,_, in_IN contrast_NN ,_, kills_VBZ the_DT parasites_NNS at_IN the_DT end_NN of_IN the_DT first_JJ cycle_NN ._SENT Consequently_RB ,_, we_PP have_VBP investigated_VBN whether_IN the_DT synergy_NN of_IN fosmidomycin_NN and_CC clindamycin_NN remains_VBZ apparent_JJ under_IN pharmacologically_RB achievable_JJ concentrations_NNS of_IN clindamycin_NN ._SENT It_PP has_VBZ been_VBN reported_VBN that_IN during_IN the_DT course_NN of_IN standard_JJ low-dose_NN clindamycin_NN therapy_NN with_IN 5_CD mg/kg_NN every_DT 8_CD h_NN ,_, minimal_JJ plasma_NN drug_NN levels_NNS of_IN 150_CD to_TO 800_CD ng/ml_NNS are_VBP achieved_VBN ._SENT The_DT broad_JJ range_NN reported_VBD possibly_RB depends_VBZ on_IN the_DT methods_NNS used_VBN for_IN drug_NN determination_NN ._SENT Therefore_RB ,_, we_PP investigated_VBD the_DT sensitivity_NN of_IN P._NP falciparum_NN to_TO fosmidomycin_NN in_IN the_DT presence_NN of_IN clindamycin_NN concentrations_NNS between_IN 42_CD ng/ml_NNS (_( 0.1_CD muM_NN )_) and_CC 850_CD ng/ml_NNS (_( 2_CD muM_NN )_) ._SENT Parasite_NN growth_NN was_VBD not_RB affected_VBN by_IN these_DT concentrations_NNS of_IN clindamycin_NN alone_RB within_IN the_DT assay_NN time_NN ,_, but_CC the_DT parasites_NNS were_VBD killed_VBN when_WRB the_DT incubation_NN time_NN was_VBD extended_VBN to_TO 4_CD days_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN the_DT presence_NN of_IN an_DT 850-ng/ml_JJ concentration_NN of_IN clindamycin_NN ,_, the_DT IC50_NN of_IN fosmidomycin_NN for_IN P._NP falciparum_NN strain_NN HB3_NP changed_VBD from_IN 82_CD to_TO 48_CD ng/ml_NNS ._SENT Remarkably_RB ,_, in_IN the_DT presence_NN of_IN a_DT 42-ng/ml_JJ concentration_NN of_IN clindamycin_NN ,_, the_DT IC50_NN of_IN fosmidomycin_NN was_VBD still_RB reduced_VBN to_TO 55_CD ng/ml_NNS ._SENT In_IN an_DT independent_JJ experiment_NN using_VBG P._NP falciparum_NN strain_NN A2_NP ,_, a_DT similar_JJ shift_NN to_TO lower_JJR IC50s_NNS was_VBD observed_VBN in_IN the_DT presence_NN of_IN clindamycin_NN ._SENT These_DT data_NNS clearly_RB demonstrate_VBP that_IN an_DT increased_VBN therapeutic_JJ response_NN can_MD be_VB expected_VBN from_IN a_DT combination_NN of_IN fosmidomycin_NN and_CC clindamycin_NN ._SENT In_IN vivo_JJ drug_NN interaction_NN ._SENT |_SYM Next_NP ,_, the_DT efficacy_NN of_IN fosmidomycin_NN plus_CC clindamycin_NN was_VBD investigated_VBN in_IN the_DT P._NP vinckei_NP mouse_NN model_NN ._SENT Mice_NNS were_VBD treated_VBN with_IN each_DT drug_NN ,_, administered_VBN in_IN doses_NNS that_WDT were_VBD calculated_VBN to_TO result_VB in_IN a_DT partial_JJ reduction_NN of_IN parasitemia_NN ._SENT In_IN parallel_NN ,_, mice_NNS were_VBD treated_VBN with_IN a_DT combination_NN of_IN these_DT drugs_NNS in_IN subtherapeutic_JJ doses_NNS ._SENT A_DT relatively_RB high_JJ dose_NN of_IN fosmidomycin_NN was_VBD chosen_VBN because_IN of_IN the_DT anticipated_JJ short_JJ half-life_NN in_IN plasma_NN ._SENT In_IN the_DT first_JJ experiment_NN ,_, the_DT mice_NNS were_VBD infected_VBN on_IN day_NN 0_CD and_CC treated_VBN on_IN days_NNS 1_CD and_CC 2_CD ._SENT To_TO assess_VB efficacy_NN ,_, parasitemia_NN was_VBD monitored_VBN on_IN days_NNS 3_CD ,_, 4_CD ,_, and_CC 5_CD ._SENT On_IN day_NN 3_CD ,_, the_DT parasitemia_NN of_IN mice_NNS treated_VBN with_IN 75_CD mg_NN of_IN fosmidomycin/kg_NN or_CC 5_CD mg_NN of_IN clindamycin/kg_NN was_VBD 7.8_CD or_CC 20_CD %_NN ,_, respectively_RB ,_, in_IN comparison_NN to_TO 42_CD %_NN in_IN untreated_JJ control_NN mice_NNS ._SENT When_WRB the_DT mice_NNS were_VBD treated_VBN with_IN a_DT combination_NN of_IN 75_CD mg_NN of_IN fosmidomycin/kg_NN and_CC 5.0_CD mg_NN of_IN clindamycin/kg_NN ,_, the_DT parasitemia_NN was_VBD approximately_RB 0.1_CD %_NN on_IN day_NN 3_CD ,_, increasing_VBG to_TO 0.2_CD %_NN on_IN day_NN 5_CD ._SENT A_DT combination_NN of_IN 75_CD mg_NN of_IN fosmidomycin/kg_NN and_CC 2.5_CD mg_NN of_IN clindamycin/kg_NN was_VBD equally_RB efficacious_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT However_RB ,_, efficacy_NN decreased_VBD significantly_RB when_WRB the_DT clindamycin_NN dose_NN was_VBD further_RBR reduced_VBN to_TO 1.3_CD mg/kg_NN (_( data_NNS not_RB shown_VBN )_) ._SENT An_DT additional_JJ study_NN was_VBD designed_VBN to_TO investigate_VB whether_IN a_DT combination_NN of_IN fosmidomycin_NN and_CC clindamycin_NN would_MD be_VB effective_JJ when_WRB treatment_NN is_VBZ initiated_VBN in_IN the_DT presence_NN of_IN high_JJ parasitemia_NN ._SENT This_DT was_VBD of_IN particular_JJ interest_NN because_IN clindamycin_NN alone_RB ,_, even_RB at_IN high_JJ doses_NNS ,_, is_VBZ not_RB able_JJ to_TO rescue_VB mice_NNS under_IN such_JJ conditions_NNS ._SENT Therefore_RB ,_, treatment_NN was_VBD started_VBN on_IN day_NN 3_CD after_IN infection_NN at_IN a_DT parasitemia_NN of_IN approximately_RB 20_CD %_NN ._SENT Following_VBG treatment_NN with_IN fosmidomycin_NN alone_RB ,_, parasitemia_NNS continued_VBD to_TO increase_VB for_IN 24_CD h_NN but_CC then_RB fell_VBD to_TO 3.9_CD %_NN by_IN day_NN 5_CD ._SENT By_IN day_NN 6_CD ,_, parasitemia_NP had_VBD reached_VBN a_DT range_NN between_IN 3.6_CD and_CC 74_CD %_NN ,_, and_CC all_DT mice_NNS ,_, even_RB those_DT with_IN only_JJ moderate_JJ parasitemia_NN ,_, had_VBD symptoms_NNS of_IN severe_JJ anemia_NN ,_, a_DT condition_NN known_VBN as_IN postschizontal_JJ anemia_NN ._SENT Treatment_NN with_IN clindamycin_NN alone_RB did_VBD not_RB stop_VB the_DT rise_NN of_IN parasitemia_NN ._SENT When_WRB fosmidomycin_NN and_CC clindamycin_NN were_VBD administered_VBN in_IN combination_NN ,_, there_EX was_VBD a_DT constant_JJ reduction_NN in_IN the_DT level_NN of_IN parasitemia_NN to_TO 0.5_CD %_NN on_IN day_NN 6_CD ._SENT Again_RB ,_, a_DT combination_NN of_IN 75_CD mg_NN of_IN fosmidomycin/kg_NN plus_CC 2.5_CD mg_NN of_IN clindamycin/kg_NN was_VBD as_RB effective_JJ as_IN 75_CD mg_NN of_IN fosmidomycin/kg_NN plus_CC 5.0_CD mg_NN of_IN clindamycin/kg_NN (_( data_NNS not_RB shown_VBN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Representative_NP isobolograms_NNS of_IN the_DT interaction_NN of_IN fosmidomycin_NN with_IN quinine_NN ,_, artemisinin_NP ,_, proguanil_NP ,_, clindamycin_NN ,_, or_CC lincomycin_NN ._SENT Representative_JJ isobolograms_NNS of_IN the_DT interaction_NN of_IN fosmidomycin_NN with_IN quinine_NN ,_, artemisinin_NP ,_, proguanil_NP ,_, clindamycin_NN ,_, or_CC lincomycin_NN ._SENT The_DT interaction_NN of_IN proguanil_NP with_IN atovaquone_NN was_VBD assessed_VBN as_IN a_DT control_NN experiment_NN (_( upper_JJ left_JJ panel_NN )_) ._SENT The_DT P._NP falciparum_NN strain_NN used_VBN for_IN each_DT experiment_NN is_VBZ indicated_VBN ._SENT FIG._NN 2_CD ._SENT |_SYM Dose_NP response_NN of_IN P._NP falciparum_NN Dose_NP response_NN of_IN P._NP falciparum_NN growth_NN to_TO fosmidomycin_NN in_IN the_DT presence_NN of_IN different_JJ constant_JJ clindamycin_NN concentrations_NNS ._SENT P._NP falciparum-infected_JJ erythrocytes_NNS were_VBD incubated_VBN with_IN a_DT serial_JJ dilution_NN of_IN fosmidomycin_NN in_IN the_DT absence_NN (_( filled_VBN circles_NNS )_) or_CC in_IN the_DT presence_NN of_IN clindamycin_NN at_IN 43_CD ng/ml_NNS (_( diamonds_NNS )_) ,_, 210_CD ng/ml_NNS (_( inverted_JJ triangles_NNS )_) ,_, or_CC 850_CD ng/ml_NNS (_( triangles_NNS )_) ._SENT Parasite_NN growth_NN was_VBD monitored_VBN by_IN radioactive_JJ hypoxanthine_NN incorporation_NN ._SENT The_DT clindamycin_NN concentrations_NNS selected_VBN did_VBD not_RB have_VB intrinsic_JJ antimalarial_JJ activity_NN under_IN the_DT assay_NN conditions_NNS ._SENT Results_NNS obtained_VBN by_IN independent_JJ experiments_NNS with_IN P._NP falciparum_NN strains_VBZ HB3_NP (_( upper_JJ panel_NN )_) and_CC A2_NP (_( lower_JJR panel_NN )_) are_VBP presented_VBN ._SENT FIG._NN 3_CD ._SENT |_SYM In_IN vivo_JJ efficacy_NN of_IN fosmidomycin_NN plus_CC clindamycin_NN in_IN P._NP vinckei_NNS In_IN vivo_JJ efficacy_NN of_IN fosmidomycin_NN plus_CC clindamycin_NN in_IN P._NP vinckei-infected_JJ mice_NNS ._SENT (_( A_NP )_) For_IN suppressive_JJ treatment_NN ,_, drugs_NNS were_VBD administered_VBN on_IN days_NNS 1_CD and_CC 2_CD postinfection_NN and_CC parasitemia_NN was_VBD monitored_VBN on_IN days_NNS 3_CD to_TO 5_CD ._SENT (_( B_NP )_) For_IN curative_JJ treatment_NN starting_VBG with_IN high_JJ parasitemia_NNS ,_, drugs_NNS were_VBD administered_VBN on_IN days_NNS 3_CD and_CC 4_CD and_CC parasitemia_NNS was_VBD monitored_VBN from_IN days_NNS 3_CD to_TO 8_CD ._SENT Geometric_JJ mean_JJ values_NNS and_CC ranges_NNS of_IN observed_JJ values_NNS are_VBP indicated_VBN ._SENT Fos_NP ,_, fosmidomycin_NP ;_: Cli_NP ,_, clindamycin_NN ._SENT TABLE_NN 1_CD |_SYM In_IN vitro_NP IC50s_NP of_IN the_DT test_NN drugs_NNS determined_VBN for_IN P._NP falciparum_NN strains_NNS 3D7_JJ ,_, HB3_NP ,_, Dd2_NP ,_, and_CC A2_NP TABLE_NP 2_CD |_SYM Interaction_NP of_IN fosmidomycin_NN with_IN other_JJ antimalarial_JJ drugs_NNS against_IN P._NP falciparum_NN in_IN vitro_NN In_IN our_PP$ in_IN vitro_NN experiments_NNS ,_, combining_VBG fosmidomycin_NN with_IN commonly_RB used_VBN antimalarial_JJ drugs_NNS resulted_VBN in_IN an_DT indifferent_JJ effect_NN in_IN most_JJS cases_NNS ,_, with_IN sum_NN FIC_JJ values_NNS between_IN 1.04_CD and_CC 1.46_CD ._SENT An_DT antagonistic_JJ effect_NN ,_, resulting_VBG in_IN sum_NN FIC_NP values_VBZ higher_JJR than_IN 2_CD ,_, refers_VBZ to_TO loss_NN of_IN activity_NN when_WRB drugs_NNS are_VBP used_VBN in_IN combination_NN ,_, indicating_VBG that_IN higher_JJR concentrations_NNS of_IN the_DT individual_JJ drugs_NNS would_MD be_VB required_VBN to_TO produce_VB the_DT same_JJ effect_NN as_IN when_WRB the_DT drugs_NNS are_VBP administered_VBN singly_RB ._SENT Such_JJ conditions_NNS ,_, however_RB ,_, were_VBD not_RB observed_VBN in_IN this_DT study_NN ._SENT Therefore_RB ,_, even_RB the_DT drugs_NNS associated_VBN with_IN an_DT indifferent_JJ effect_NN in_IN vitro_NN may_MD prove_VB to_TO be_VB useful_JJ therapeutic_JJ partners_NNS for_IN fosmidomycin_NN ._SENT In_IN this_DT regard_NN ,_, a_DT combination_NN of_IN fosmidomycin_NN with_IN an_DT artemisinin_NN derivative_NN may_MD be_VB of_IN particular_JJ interest_NN ._SENT Artemisinin_NN derivatives_NNS such_JJ as_IN artesunate_NN and_CC artemether_NN have_VBP been_VBN successfully_RB employed_VBN in_IN various_JJ drug_NN combinations_NNS ,_, since_IN they_PP are_VBP active_JJ against_IN multidrug-resistant_JJ parasites_NNS ,_, display_VBP a_DT favorable_JJ safety_NN profile_NN ,_, and_CC rapidly_RB reduce_VB the_DT parasite_NN load_NN within_IN one_CD replication_NN cycle_NN ._SENT The_DT additive_JJ effect_NN observed_VBD with_IN quinine_NN may_MD become_VB relevant_JJ in_IN severe_JJ malaria_NN ,_, where_WRB intravenous_JJ quinine_NN ,_, commonly_RB given_VBN in_IN combination_NN with_IN doxycycline_NN ,_, is_VBZ still_RB the_DT first_JJ choice_NN of_IN treatment_NN ._SENT Since_IN the_DT use_NN of_IN doxycycline_NN is_VBZ not_RB appropriate_JJ for_IN young_JJ children_NNS and_CC pregnant_JJ women_NNS ,_, there_EX would_MD seem_VB to_TO be_VB a_DT case_NN for_IN replacing_VBG it_PP with_IN fosmidomycin_NN in_IN view_NN of_IN the_DT more_RBR rapid_JJ action_NN of_IN the_DT latter_NN ._SENT Our_PP$ studies_NNS have_VBP provided_VBN conclusive_JJ evidence_NN of_IN potent_JJ in_IN vitro_NP synergistic_JJ activity_NN between_IN fosmidomycin_NN and_CC the_DT lincosamide_NN antibiotics_NNS lincomycin_NN and_CC clindamycin_NN ._SENT This_DT has_VBZ also_RB been_VBN established_VBN in_IN a_DT malaria_NN mouse_NN model_NN ,_, even_RB when_WRB treatment_NN was_VBD delayed_VBN pending_VBG the_DT development_NN of_IN high_JJ parasitemia_NN ._SENT While_IN lincomycin_NN as_IN the_DT natural_JJ precursor_NN of_IN clindamycin_NN is_VBZ of_IN only_RB historical_JJ interest_NN ,_, clindamycin_NN is_VBZ widely_RB used_VBN for_IN treating_VBG infections_NNS with_IN gram-positive_JJ or_CC anaerobic_JJ bacteria_NNS ._SENT In_IN addition_NN ,_, it_PP is_VBZ active_JJ against_IN parasites_NNS of_IN the_DT phylum_NN Apicomplexa_NP ,_, which_WDT includes_VBZ Plasmodium_NN ,_, Theileria_NP ,_, and_CC Toxoplasma_NP ._SENT Clindamycin_NN is_VBZ believed_VBN to_TO target_VB the_DT prokaryote-like_JJ ribosomes_NNS of_IN the_DT apicoplast_NN ._SENT By_IN this_DT means_NN ,_, self-replication_NN of_IN the_DT organelle_NN is_VBZ inhibited_VBN ,_, leading_VBG to_TO the_DT death_NN of_IN the_DT parasite_NN in_IN the_DT second_JJ replication_NN cycle_NN ._SENT The_DT fact_NN that_IN fosmidomycin_NN inhibits_VBZ DOXP_NP reductoisomerase_NN ,_, an_DT enzyme_NN that_WDT is_VBZ localized_VBN in_IN the_DT apicoplast_NN ,_, may_MD provide_VB an_DT explanation_NN for_IN the_DT observed_JJ synergy_NN with_IN the_DT lincosamides_NNS ._SENT However_RB ,_, it_PP is_VBZ not_RB yet_RB clear_JJ why_WRB other_JJ antibiotics_NNS that_WDT are_VBP also_RB believed_VBN to_TO impair_VB apicoplast_NN function_NN do_VBP not_RB exhibit_VB such_JJ synergy_NN ._SENT Possibly_RB ,_, clindamycin_NN facilitates_VBZ the_DT transport_NN of_IN fosmidomycin_NN into_IN the_DT parasite_NN or_CC the_DT apicoplast_NN by_IN an_DT unknown_JJ mechanism_NN ._SENT Early_JJ studies_NNS on_IN the_DT effectiveness_NN of_IN clindamycin_NN as_IN an_DT antimalarial_JJ agent_NN were_VBD very_RB promising_JJ ._SENT However_RB ,_, in_IN view_NN of_IN its_PP$ slow_JJ onset_NN of_IN action_NN ,_, the_DT use_NN of_IN clindamycin_NN as_IN a_DT single_JJ entity_NN is_VBZ restricted_VBN to_TO the_DT treatment_NN of_IN asymptomatic_JJ or_CC uncomplicated_JJ P._NP falciparum_NN malaria_NN ._SENT It_PP is_VBZ also_RB useful_JJ as_IN a_DT therapeutic_JJ partner_NN in_IN antimalarial-drug_NN combinations_NNS ._SENT In_IN Gabon_NP ,_, all_DT of_IN 38_CD adult_JJ patients_NNS receiving_VBG 5_CD mg_NN of_IN clindamycin/kg_NN twice_RB daily_JJ for_IN 5_CD days_NNS were_VBD cured_VBN ,_, with_IN only_RB 1_CD patient_NN developing_VBG a_DT recurrent_JJ parasitemia_NN which_WDT may_MD have_VB been_VBN due_JJ to_TO reinfection_NN ._SENT The_DT same_JJ regimen_NN led_VBN to_TO a_DT 100_CD %_NN cure_NN rate_NN for_IN 35_CD patients_NNS in_IN Brazil_NP ._SENT A_DT quinine-clindamycin_NN combination_NN was_VBD effective_JJ against_IN multidrug-resistant_JJ malaria_NN in_IN Thailand_NP ._SENT Furthermore_RB ,_, a_DT 3-day_JJ course_NN of_IN clindamycin_NN plus_CC quinine_NN was_VBD curative_JJ in_IN the_DT treatment_NN of_IN uncomplicated_JJ P._NP falciparum_NN malaria_NN ,_, compared_VBN to_TO 7_CD days_NNS of_IN treatment_NN with_IN quinine_NN alone_RB ._SENT Since_IN clindamycin_NN has_VBZ been_VBN used_VBN only_RB for_IN a_DT relatively_RB small_JJ number_NN of_IN malaria_NN patients_NNS ,_, it_PP is_VBZ not_RB expected_VBN that_IN resistant_JJ parasites_NNS have_VBP developed_VBN in_IN the_DT field_NN ._SENT As_IN a_DT therapeutic_JJ partner_NN for_IN fosmidomycin_NN ,_, clindamycin_NN has_VBZ the_DT advantage_NN of_IN having_VBG a_DT similarly_RB short_JJ half-life_NN in_IN plasma_NN ._SENT As_IN a_DT consequence_NN ,_, repeated_JJ dosing_VBG will_MD be_VB necessary_JJ ,_, but_CC the_DT parasites_NNS will_MD be_VB exposed_VBN to_TO subtherapeutic_JJ drug_NN concentrations_NNS for_IN a_DT short_JJ time_NN only_RB ,_, thereby_RB deterring_VBG the_DT emergence_NN of_IN resistance_NN ._SENT Furthermore_RB ,_, the_DT safety_NN of_IN clindamycin_NN as_IN an_DT antibacterial_NN agent_NN has_VBZ been_VBN substantiated_VBN through_IN 35_CD years_NNS of_IN clinical_JJ experience_NN (_( ,_, ,_, 23_CD )_) ._SENT In_IN addition_NN to_TO its_PP$ potential_JJ use_NN as_IN an_DT effective_JJ and_CC affordable_JJ medication_NN for_IN uncomplicated_JJ malaria_NN ,_, fosmidomycin_NN plus_CC clindamycin_NN may_MD be_VB of_IN particular_JJ value_NN for_IN the_DT treatment_NN of_IN severe_JJ malaria_NN when_WRB patients_NNS are_VBP not_RB able_JJ to_TO tolerate_VB oral_JJ medication_NN ._SENT Conventional_JJ treatment_NN with_IN intravenous_JJ quinine_NN may_MD be_VB life-threatening_JJ when_WRB the_DT required_JJ dose_NN is_VBZ infused_VBN too_RB rapidly_RB ._SENT Parenteral_JJ administration_NN of_IN several_JJ highly_RB potent_JJ drugs_NNS such_JJ as_IN mefloquine_NN ,_, halofantrine_NN ,_, and_CC atovaquone_NN is_VBZ precluded_VBN by_IN their_PP$ poor_JJ solubility_NN ._SENT Fosmidomycin_NP ,_, in_IN contrast_NN ,_, is_VBZ freely_RB water_NN soluble_JJ ,_, and_CC bolus_NN infusions_NNS of_IN as_RB much_JJ as_IN 2_CD g_NN were_VBD well_RB tolerated_VBN in_IN a_DT phase_NN I_PP volunteer_VBP study_NN ._SENT Also_RB ,_, clindamycin_NN ,_, in_IN the_DT form_NN of_IN its_PP$ phosphonic_JJ acid_NN ester_NN ,_, is_VBZ available_JJ as_IN an_DT intravenous_JJ formulation_NN ._SENT Therefore_RB ,_, development_NN of_IN an_DT intravenous_JJ formulation_NN of_IN a_DT combination_NN of_IN fosmidomycin_NN and_CC clindamycin_NN for_IN treatment_NN of_IN severe_JJ malaria_NN should_MD be_VB technically_RB feasible_JJ ._SENT However_RB ,_, the_DT role_NN of_IN the_DT combination_NN of_IN fosmidomycin_NN and_CC clindamycin_NN in_IN the_DT treatment_NN of_IN acute_JJ uncomplicated_JJ P._NP falciparum_NN malaria_NN will_MD first_RB be_VB established_VBN through_IN an_DT extended_JJ program_NN of_IN phase_NN II_CD studies_NNS ._SENT The_DT first_JJ clinical_JJ studies_NNS are_VBP currently_RB ongoing_JJ in_IN Gabon_NP and_CC Thailand_NP ._SENT 